UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune mechanisms in arterial hypertension. Recent advances

Cell and tissue research, 2021-08, Vol.385 (2), p.393-404

2021

Volltextzugriff (PDF)

Salt, inflammation, IL‐17 and hypertension

British journal of pharmacology, 2019-06, Vol.176 (12), p.1853-1863

2019

Volltextzugriff (PDF)

B6.Rag1 Knockout Mice Generated at the Jackson Laboratory in 2009 Show a Robust Wild-Type Hypertensive Phenotype in Response to Ang II (Angiotensin II)

Hypertension (Dallas, Tex. 1979), 2020-04, Vol.75 (4), p.1110-1116

2020

Volltextzugriff (PDF)

The role of complement in arterial hypertension and hypertensive end organ damage

British journal of pharmacology, 2021-07, Vol.178 (14), p.2849-2862

2021

Volltextzugriff (PDF)

A pathogenic role of complement in arterial hypertension and hypertensive end organ damage

American journal of physiology. Heart and circulatory physiology, 2017-03, Vol.312 (3), p.H349-H354

2017

Volltextzugriff (PDF)

DEFICIENCY OF THE COMPLEMENT RECEPTOR C5AR2 HAS NO EFFECT ON BLOOD PRESSURE AND END ORGAN DAMAGE IN ANGIOTENSIN II INDUCED HYPERTENSION

Journal of hypertension, 2024-05, Vol.42 (Suppl 1), p.e44

2024

Volltextzugriff (PDF)

Finerenone Reduces Renal ROR[gamma]t [gamma][delta] T Cells and Protects against Cardiorenal Damage

American journal of nephrology, 2022-08, Vol.53 (7), p.552

2022

Volltextzugriff (PDF)

Role of the Anaphylatoxin Receptor C5aR2 in Angiotensin II-Induced Hypertension and Hypertensive End-Organ Damage

American journal of hypertension, 2024-09, Vol.37 (10), p.810-825

2024

Volltextzugriff (PDF)

The role of the mineralocorticoid receptor in immune cells in cardiovascular disease

British journal of pharmacology, 2022-07, Vol.179 (13), p.3135-3151

2022

Volltextzugriff (PDF)

DEFICIENCY OF COMPLEMENT C3A AND C5A RECEPTORS DOES NOT PREVENT ANGIOTENSIN II–INDUCED HYPERTENSION AND HYPERTENSIVE END ORGAN DAMAGE

Journal of hypertension, 2023-06, Vol.41 (Suppl 3), p.e12-e13

2023

Volltextzugriff (PDF)

Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia

Kidney international, 2024-04, Vol.105 (4), p.877-881

2024

Volltextzugriff (PDF)

Deficiency of Complement C3a and C5a receptors Does Not Prevent Angiotensin II–Induced Hypertension and Hypertensive End-Organ Damage

Hypertension (Dallas, Tex. 1979), 2024-01, Vol.81 (1), p.138-150

2024

Volltextzugriff (PDF)

Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease

British journal of pharmacology, 2023-09, Vol.180 (18), p.2412-2435

2023

Volltextzugriff (PDF)

The complement receptor C5aR2 is protective in hypertensive end organ damage

Molecular immunology, 2018-10, Vol.102, p.135-135

2018

Volltextzugriff (PDF)

Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage

American journal of nephrology, 2022, Vol.53 (7), p.552-564

2022

Volltextzugriff (PDF)

Adaptive immunity and IL‐17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice

British journal of pharmacology, 2019-06, Vol.176 (12), p.2002-2014

2019

Volltextzugriff (PDF)

Functional Outcome Following Stroke Thrombectomy in Clinical Practice

Stroke (1970), 2019-09, Vol.50 (9), p.2500-2506

2019

Volltextzugriff (PDF)

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Journal of clinical oncology, 2003-12, Vol.21 (24), p.4489-4495

2003

Volltextzugriff (PDF)

Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment

International journal of stroke, 2019-06, Vol.14 (4), p.372-380

2019

Volltextzugriff (PDF)

Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma

Annals of neurology, 2010-02, Vol.67 (2), p.182-189

2010

Volltextzugriff (PDF)

Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma

Neurology, 2020-12, Vol.95 (23), p.e3138

2020

Volltextzugriff (PDF)

Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial

Critical care and resuscitation, 2024-06, Vol.26 (2), p.80-86

2024

Volltextzugriff (PDF)

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

Journal of neuro-oncology, 2009-02, Vol.91 (3), p.299-305

2009

Volltextzugriff (PDF)

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

Neuro-oncology (Charlottesville, Va.), 2010-07, Vol.12 (7), p.720-724

2010

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Humans
(12)
Male
(10)
Animals
(7)
Hypertension
(7)
Middle Aged
(7)
Aged
(6)
Clinical Neurology
(6)
Female
(6)
Neurosciences & Neurology
(6)
Adult
(5)
Blood Pressure
(5)
Cardiovascular System & Cardiology
(5)
Central Nervous System Neoplasms - Drug Therapy
(5)
Lymphoma - Drug Therapy
(5)
Peripheral Vascular Disease
(5)
Pharmacology & Pharmacy
(5)
Treatment Outcome
(5)
Adaptive Immunity
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immune mechanisms in arterial hypertension. Recent advances

Salt, inflammation, IL‐17 and hypertension

B6.Rag1 Knockout Mice Generated at the Jackson Laboratory in 2009 Show a Robust Wild-Type Hypertensive Phenotype in Response to Ang II (Angiotensin II)

The role of complement in arterial hypertension and hypertensive end organ damage

A pathogenic role of complement in arterial hypertension and hypertensive end organ damage

DEFICIENCY OF THE COMPLEMENT RECEPTOR C5AR2 HAS NO EFFECT ON BLOOD PRESSURE AND END ORGAN DAMAGE IN ANGIOTENSIN II INDUCED HYPERTENSION

Finerenone Reduces Renal ROR[gamma]t [gamma][delta] T Cells and Protects against Cardiorenal Damage

Role of the Anaphylatoxin Receptor C5aR2 in Angiotensin II-Induced Hypertension and Hypertensive End-Organ Damage

The role of the mineralocorticoid receptor in immune cells in cardiovascular disease

DEFICIENCY OF COMPLEMENT C3A AND C5A RECEPTORS DOES NOT PREVENT ANGIOTENSIN II–INDUCED HYPERTENSION AND HYPERTENSIVE END ORGAN DAMAGE

Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia

Deficiency of Complement C3a and C5a receptors Does Not Prevent Angiotensin II–Induced Hypertension and Hypertensive End-Organ Damage

Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease

The complement receptor C5aR2 is protective in hypertensive end organ damage

Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage

Adaptive immunity and IL‐17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice

Functional Outcome Following Stroke Thrombectomy in Clinical Practice

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment

Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma

Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma

Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

Suchergebnisse filtern